Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is making significant strides in its evolution from a development-stage biotechnology company to a commercial-stage biopharmaceutical entity, highlighted by the FDA approval and commercial launch of LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma. This milestone, coupled with a robust late-stage pipeline, positions the company to capitalize on significant unmet medical needs across multiple therapeutic areas.
The commercial launch of LYMPHIR in December 2025 has already generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. Payer coverage has been broad, with nearly 100% of covered commercial lives and 83% of targeted accounts achieving formulary inclusion or under active review as of May 2026. Beyond the U.S., Citius Oncology, the company's oncology-focused subsidiary, announced an initial shipment of LYMPHIR to Europe in April 2026, signaling expansion into international markets. The company is also exploring additional oncology indications for LYMPHIR, with positive topline results from two Phase 1 investigator-initiated studies: one combining LYMPHIR with pembrolizumab in recurrent or refractory gynecologic cancers, and another in high-risk relapsed or refractory diffuse large B-cell lymphoma prior to CAR-T therapy.
Citius's late-stage pipeline includes Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). This therapy addresses a critical need, as there are currently no FDA-approved treatments specifically for salvaging infected catheters. Mino-Lok met its primary and secondary endpoints in a pivotal Phase 3 superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company has received guidance from the FDA outlining a pathway to support a future New Drug Application submission, with worldwide sales potential estimated at approximately $1.8 billion.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million people in the U.S. reporting hemorrhoid symptoms annually and no FDA-approved prescription products for this indication, Halo-Lido could become the first if approved. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls, warranting further studies.
The company's leadership team, with decades of pharmaceutical experience, is steering this diversified portfolio. Leonard Mazur, CEO and Chairman, and Myron Holubiak, Executive Vice Chairman, bring extensive backgrounds in development, commercialization, and sales. Citius's strategy focuses on products with significant unmet medical needs and differentiated commercial opportunities, combining an FDA-approved commercial product with multiple clinical-stage programs to create several potential paths for value creation.
As Citius continues to engage with regulators and expand LYMPHIR's reach, the company is well-positioned to leverage its commercial-stage asset and late-stage pipeline to drive growth. The successful launch of LYMPHIR not only provides a revenue stream but also validates the company's ability to commercialize therapies, setting the stage for potential future launches of Mino-Lok and Halo-Lido.
